Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here are the top picks from rising hedge fund stars at Sohn, including one that could nearly double

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Buy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares

Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why

Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win

Paltusotine: A Potential Game-Changer in Acromegaly Treatment, Analyst Recommends Buy

UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study

Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Crinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion Potential

Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)